Hutchmed (HCM) stock rises despite a 2024 revenue miss as a cancer drug combo it developed with Innovent Biologics (IVBYI) ...

The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure ...

Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this ...

Heart failure is a major health concern, especially for aging populations—it significantly increases mortality rates, and ...